Making big drugs during troubled times - (Jul. 9, 2009)

Amgen CEO Kevin Sharer's job is to produce blockbuster drugs. Will health-care reform make that harder?(Fortune Magazine)—These are momentous times for Amgen, the world's largest biotech company. The health-care revolution brewing in Washington could be dramatically good news or bad for a business whose drugs tend to be life-changing—and highly expensive. Also on deck this year is a critical FDA decision on Amgen's denosumab, a possible blockbuster treatment for osteoporosis and bone cancer o...